Aeterna Zentaris (AEZS) lands IND FDA approval for the initiation of a Phase 2A trial to assess...

|By:, SA News Editor

Aeterna Zentaris (AEZS) lands IND FDA approval for the initiation of a Phase 2A trial to assess the firm's treatment for cancer cachexia. The firm says if its AEZS-130 drug is effective, subjects could receive more effective doses of chemotherapy and have a better functional status.